Trial Outcomes & Findings for PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib (NCT NCT00548093)

Last Updated: 2019-05-21

Results Overview

BOR:best response recorded from treatment start until disease progression as per Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response: disappearance of all lesions. Partial Response (PR):greater than or equal to (\>=)30% decrease in sum of longest diameters (SLDs) of target lesions (TLs) taking as reference baseline SLD. Progressive disease (PD):\>=20% increase in SLD of TLs taking as reference smallest SLD since treatment start, or appearance of \>=1 new lesion. Stable disease:neither shrinkage for PR nor increase for PD taking as reference smallest SLD since treatment start.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

66 participants

Primary outcome timeframe

Baseline, end of every even-numbered cycle up to end of treatment (Day 936)

Results posted on

2019-05-21

Participant Flow

Participant milestones

Participant milestones
Measure	PF-00299804 (Adenocarcinoma Histology) Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Overall Study STARTED	50	16
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	50	16

Reasons for withdrawal

Reasons for withdrawal
Measure	PF-00299804 (Adenocarcinoma Histology) Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Overall Study Death	33	13
Overall Study Lost to Follow-up	3	1
Overall Study Objective progression or relapse	1	1
Overall Study Other	11	1
Overall Study Withdrawal by Subject	1	0
Overall Study Completed post-treatment follow-up	1	0

Baseline Characteristics

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=16 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	Total n=66 Participants Total of all reporting groups
Age, Continuous	60.7 years STANDARD_DEVIATION 9.3 • n=5 Participants	65.0 years STANDARD_DEVIATION 10.7 • n=7 Participants	61.7 years STANDARD_DEVIATION 9.7 • n=5 Participants
Sex: Female, Male Female	35 Participants n=5 Participants	2 Participants n=7 Participants	37 Participants n=5 Participants
Sex: Female, Male Male	15 Participants n=5 Participants	14 Participants n=7 Participants	29 Participants n=5 Participants

PRIMARY outcome

Timeframe: Baseline, end of every even-numbered cycle up to end of treatment (Day 936)

Population: Response-evaluable population included all enrolled participants who received at least 1 dose of study treatment, with adequate baseline tumor assessment and at least 1 on-study tumor assessment after the first dosing.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=42 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Best Overall Response (BOR) in Participants With Adenocarcinoma Histology Complete response	0 Participants	—
Best Overall Response (BOR) in Participants With Adenocarcinoma Histology Partial response	2 Participants	—
Best Overall Response (BOR) in Participants With Adenocarcinoma Histology Stable or No response	28 Participants	—
Best Overall Response (BOR) in Participants With Adenocarcinoma Histology Objective progression	12 Participants	—
Best Overall Response (BOR) in Participants With Adenocarcinoma Histology Indeterminate	0 Participants	—

SECONDARY outcome

Timeframe: Baseline, end of every even-numbered cycle up to end of treatment (Day 936)

BOR: best response recorded from treatment start until disease progression as per RECIST. Complete Response: disappearance of all lesions. PR: \>=30% decrease in SLDs of TLs taking as reference baseline SLD. PD: \>=20% increase in SLD of TLs taking as reference smallest SLD since treatment start, or appearance of \>=1 new lesion. Stable disease: neither shrinkage for PR nor increase for PD taking as reference smallest SLD since treatment start.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=16 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Best Overall Response (BOR) in Participants With Non-Adenocarcinoma Histology Complete response	0 Participants	—
Best Overall Response (BOR) in Participants With Non-Adenocarcinoma Histology Partial response	1 Participants	—
Best Overall Response (BOR) in Participants With Non-Adenocarcinoma Histology Stable or no response	8 Participants	—
Best Overall Response (BOR) in Participants With Non-Adenocarcinoma Histology Objective progression	7 Participants	—
Best Overall Response (BOR) in Participants With Non-Adenocarcinoma Histology Indeterminate	0 Participants	—

SECONDARY outcome

Timeframe: Baseline, end of every even-numbered cycle up to end of treatment (Day 936)

Population: DR was calculated for the subgroup of participants from the response-evaluable population, with a confirmed objective tumor response (CR or PR).

Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=2 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=1 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Duration of Response (DR)	45.2 weeks Interval 24.1 to 66.3	12.1 weeks 95% confidence interval was not estimable since only one participant was evaluable.

SECONDARY outcome

Timeframe: Up to 6 months after the start of study medication

Population: As-enrolled population included all participants who were enrolled in the study.

Probability of being event free (event defined as PD or death due to any cause) at 6 months after the first dose of study treatment. PFS was defined as the time from the first dosing date to the date of first documentation of progression or death due to any cause, whichever occurs first. PFS was calculated as (first event date (if not reached, censored at the last known event-free date) minus first dosing date plus 1). Documentation of progression was determined from objective disease assessment based on RECIST v1.0 criteria. PD was defined as at least a 20% increase in the sum of the longest diameters of the target lesions taking as a reference the smallest sum of the longest diameters recorded since treated started or the appearance of 1 or more new lesions.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=16 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Percent Probability of Progression-free Survival (PFS) at Month 6	24.3 percent chance of being event-free Interval 12.4 to 38.4	8.0 percent chance of being event-free Interval 0.5 to 29.8

SECONDARY outcome

Timeframe: Months 6, 12

Population: As-enrolled population included all participants who were enrolled in the study.

Probability of being alive at 6 and 12 months after the first dose of study medication.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=16 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Percent Probability of Overall Survival at Months 6 and 12 Month 6	71.5 percent chance of being alive Interval 56.7 to 82.1	50.0 percent chance of being alive Interval 24.5 to 71.0
Percent Probability of Overall Survival at Months 6 and 12 Month 12	46.3 percent chance of being alive Interval 31.4 to 59.9	21.9 percent chance of being alive Interval 5.6 to 44.9

SECONDARY outcome

Timeframe: 0.5-2, 3-5, 6-8, 22-26 hours post dose on Day 1 of Cycle 1

Population: PK concentration population included all enrolled participants who received at least 1 dose of study treatment and had at least 1 measured plasma concentration. Here, 'N' (overall number of participants analyzed) signifies those participants who were evaluable for the measure.

The pharmacokinetic (PK) samples collected between 22-26 hours post dose on Day 1 of Cycle 1 were within the pre-specified time window for the 24-hour post dose sample and were used for calculation of AUC (0-24) on Day 1 of Cycle 1.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=49 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=13 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)]	390.8 nanogramhour per milliliter (nghr/mL) Standard Deviation 165.24	397.9 nanogramhour per milliliter (nghr/mL) Standard Deviation 258.11

SECONDARY outcome

Timeframe: 0.5-2, 3-5, 6-8, 22-26 hours post dose on Day 1 of Cycle 1

Population: PK concentration population included all enrolled participants who received at least 1 dose of study treatment and had at least 1 measured plasma concentration. Here, 'N' signifies those participants who were evaluable for the measure.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=49 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=13 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Maximum Observed Plasma Concentration (Cmax)	22.61 nanogram per milliliter Standard Deviation 10.315	25.49 nanogram per milliliter Standard Deviation 22.533

SECONDARY outcome

Timeframe: 0.5-2, 3-5, 6-8, 22-26 hours post dose on Day 1 of Cycle 1

Population: PK concentration population included all enrolled participants who received at least 1 dose of study treatment and had at least 1 measured plasma concentration. Here, 'N' signifies those participants who were evaluable for the measure.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=49 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=13 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Time to Reach Maximum Observed Plasma Concentration (Tmax)	6.08 hours Interval 3.0 to 25.1	6.17 hours Interval 5.0 to 25.7

SECONDARY outcome

Timeframe: Baseline [pre-dose on Cycle 1 Day 1 (C1D1)], then pre-dose on Day 1 of each cycle, end of treatment (Day 936)

Population: The pharmacodynamic population was defined as members of the ITT (as enrolled) population who had baseline samples submitted per Institutional Review Board (IRB) / Independent Ethics Committee (IEC) approval and participant consent. Here, 'number analyzed' signifies participants evaluable at each time point for each arm respectively.

Human epidermal growth factor receptor 2 (HER2) is a transmembrane protein that plays a pivotal role in growth factor signal transduction and epidermal growth factor receptor (EGFR) is a cell surface protein that binds to epidermal growth factor. Levels of the HER-2 and EGFR extracellular domains in serum were assessed by enzyme-linked immunosorbent assay (ELISA).

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=48 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=14 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C1D1	51.25 ng/mL Standard Deviation 14.86	57.28 ng/mL Standard Deviation 15.36
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C5D1	45.35 ng/mL Standard Deviation 11.32	51.2 ng/mL Standard Deviation 9.76
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C6D1	48.71 ng/mL Standard Deviation 12.01	66.52 ng/mL Standard Deviation 20.19
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C7D1	52.85 ng/mL Standard Deviation 15.6	44.29 ng/mL Standard Deviation 9.55
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C8D1	50.27 ng/mL Standard Deviation 17.05	55.93 ng/mL Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C9D1	50.68 ng/mL Standard Deviation 11.41	—
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C10D1	50.45 ng/mL Standard Deviation 11.58	—
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C2D1	8.2 ng/mL Standard Deviation 3.28	9.39 ng/mL Standard Deviation 9.18
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C4D1	7.22 ng/mL Standard Deviation 2.25	6.6 ng/mL Standard Deviation 2.44
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C2D1	45.89 ng/mL Standard Deviation 12.42	51.05 ng/mL Standard Deviation 11.35
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C3D1	44.91 ng/mL Standard Deviation 11.43	46.79 ng/mL Standard Deviation 7.64
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum EGFR: C4D1	46.26 ng/mL Standard Deviation 11.7	46.72 ng/mL Standard Deviation 9.01
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C1D1	9.69 ng/mL Standard Deviation 4.18	9.57 ng/mL Standard Deviation 10.27
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C3D1	7.21 ng/mL Standard Deviation 2.31	6.46 ng/mL Standard Deviation 2.92
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C5D1	7.02 ng/mL Standard Deviation 1.8	8.38 ng/mL Standard Deviation 3.54
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C6D1	7.74 ng/mL Standard Deviation 4.55	9.9 ng/mL Standard Deviation 7.34
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C7D1	6.95 ng/mL Standard Deviation 2.46	6.7 ng/mL Standard Deviation 0.42
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C8D1	6.61 ng/mL Standard Deviation 2.95	11.7 ng/mL Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C9D1	10.23 ng/mL Standard Deviation 11.66	—
Human Epidermal Growth Factor-2 (HER-2) and Epidermal Growth Factor Receptor (EGFR) Levels in Serum HER2: C10D1	6.00 ng/mL Standard Deviation 2.67	—

SECONDARY outcome

Timeframe: Screening

Population: As-enrolled population included all participants who were enrolled in the study.

HER-family is a family of transmembrane protein that plays a pivotal role in growth factor signal transduction and Kirsten Rat Sarcoma (KRAS) gene is an oncogene that encodes a small guanosine triphosphatase (GTPase) transductor protein called KRAS. The mutation status of HER and KRAS genes in tumor DNA present in plasma was determined using a polymerase chain reaction (PCR)-based assay. The gene that is most common in a particular natural population is known as the wild type. Any form of the gene other than the wild type is known as a mutant form. Number of participants with HER-Family and KRAS gene mutation were classified as: wild type, mutant and unknown.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=16 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Number of Participants With Human Epidermal Growth Factor Family (HER-Family) and Kirsten Rat Sarcoma (KRAS) Gene Mutation Status From Free Tumor Deoxy- Ribonucleic Acid (DNA) in Blood at Screening KRAS mutation: Unknown	11 Participants	1 Participants
Number of Participants With Human Epidermal Growth Factor Family (HER-Family) and Kirsten Rat Sarcoma (KRAS) Gene Mutation Status From Free Tumor Deoxy- Ribonucleic Acid (DNA) in Blood at Screening HER-2 mutation: Wild-type	29 Participants	13 Participants
Number of Participants With Human Epidermal Growth Factor Family (HER-Family) and Kirsten Rat Sarcoma (KRAS) Gene Mutation Status From Free Tumor Deoxy- Ribonucleic Acid (DNA) in Blood at Screening KRAS mutation: Wild-type	39 Participants	15 Participants
Number of Participants With Human Epidermal Growth Factor Family (HER-Family) and Kirsten Rat Sarcoma (KRAS) Gene Mutation Status From Free Tumor Deoxy- Ribonucleic Acid (DNA) in Blood at Screening KRAS mutation: Mutant	0 Participants	0 Participants
Number of Participants With Human Epidermal Growth Factor Family (HER-Family) and Kirsten Rat Sarcoma (KRAS) Gene Mutation Status From Free Tumor Deoxy- Ribonucleic Acid (DNA) in Blood at Screening HER-2 mutation: Mutant	0 Participants	0 Participants
Number of Participants With Human Epidermal Growth Factor Family (HER-Family) and Kirsten Rat Sarcoma (KRAS) Gene Mutation Status From Free Tumor Deoxy- Ribonucleic Acid (DNA) in Blood at Screening HER-2 mutation: Unknown	21 Participants	3 Participants

SECONDARY outcome

Timeframe: Baseline (C1D1), C2D1 thereafter every subsequent cycle up to C43

Population: As-enrolled population included all participants who were enrolled in the study. Here, 'N' signifies those participants who were evaluable for the measure and 'number analyzed' signifies participants evaluable at each time point for each arm respectively.

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=15 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Role functioning	72.67 units on a scale Standard Deviation 33.46	74.44 units on a scale Standard Deviation 32.04
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Emotional Functioning	77.72 units on a scale Standard Deviation 23.87	77.22 units on a scale Standard Deviation 16.51
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Cognitive Functioning	81.33 units on a scale Standard Deviation 24.89	76.67 units on a scale Standard Deviation 28.73
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Social Functioning	76.33 units on a scale Standard Deviation 30.69	67.78 units on a scale Standard Deviation 26.33
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Fatigue	36.44 units on a scale Standard Deviation 25.99	44.44 units on a scale Standard Deviation 26.89
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Nausea, vomiting	10.33 units on a scale Standard Deviation 18.10	10.00 units on a scale Standard Deviation 17.59
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Dyspnoea	30.00 units on a scale Standard Deviation 31.77	20.00 units on a scale Standard Deviation 27.60
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Insomnia	28.00 units on a scale Standard Deviation 31.12	35.56 units on a scale Standard Deviation 34.43
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Appetite loss	22.00 units on a scale Standard Deviation 30.57	31.11 units on a scale Standard Deviation 29.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Constipation	16.00 units on a scale Standard Deviation 27.14	24.44 units on a scale Standard Deviation 32.04
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Diarrhea	8.00 units on a scale Standard Deviation 15.88	4.44 units on a scale Standard Deviation 11.73
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: GHS	63.83 units on a scale Standard Deviation 24.64	63.46 units on a scale Standard Deviation 17.19
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Nausea, vomiting	8.71 units on a scale Standard Deviation 12.18	6.41 units on a scale Standard Deviation 10.84
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Insomnia	19.70 units on a scale Standard Deviation 28.14	17.95 units on a scale Standard Deviation 32.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Appetite loss	31.82 units on a scale Standard Deviation 34.44	38.46 units on a scale Standard Deviation 35.61
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Constipation	12.88 units on a scale Standard Deviation 24.08	10.26 units on a scale Standard Deviation 21.01
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Physical functioning	79.15 units on a scale Standard Deviation 21.59	62.22 units on a scale Standard Deviation 30.66
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Dyspnoea	24.56 units on a scale Standard Deviation 32.59	22.22 units on a scale Standard Deviation 21.71
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Insomnia	21.37 units on a scale Standard Deviation 30.09	27.78 units on a scale Standard Deviation 39.78
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Appetite loss	38.46 units on a scale Standard Deviation 36.30	44.44 units on a scale Standard Deviation 38.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Constipation	9.17 units on a scale Standard Deviation 21.33	25.00 units on a scale Standard Deviation 35.18
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Nausea, vomiting	5.56 units on a scale Standard Deviation 10.34	10.42 units on a scale Standard Deviation 17.68
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Physical functioning	78.52 units on a scale Standard Deviation 18.24	63.81 units on a scale Standard Deviation 34.18
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Social Functioning	81.48 units on a scale Standard Deviation 20.32	57.14 units on a scale Standard Deviation 41.79
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Diarrhea	46.15 units on a scale Standard Deviation 29.93	38.10 units on a scale Standard Deviation 29.99
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Financial difficulties	17.28 units on a scale Standard Deviation 23.33	33.33 units on a scale Standard Deviation 38.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Cognitive Functioning	84.26 units on a scale Standard Deviation 17.59	83.33 units on a scale Standard Deviation 28.87
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Social Functioning	83.33 units on a scale Standard Deviation 19.80	83.33 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Dyspnoea	20.37 units on a scale Standard Deviation 25.92	13.33 units on a scale Standard Deviation 18.26
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: GHS	65.28 units on a scale Standard Deviation 26.07	68.75 units on a scale Standard Deviation 17.18
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Pain	14.29 units on a scale Standard Deviation 21.54	20.83 units on a scale Standard Deviation 20.97
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Dyspnoea	19.05 units on a scale Standard Deviation 21.54	16.67 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Insomnia	26.19 units on a scale Standard Deviation 32.50	16.67 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Role functioning	84.72 units on a scale Standard Deviation 21.86	55.56 units on a scale Standard Deviation 50.92
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Emotional Functioning	80.77 units on a scale Standard Deviation 22.92	61.11 units on a scale Standard Deviation 33.68
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Social Functioning	87.18 units on a scale Standard Deviation 18.20	83.33 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	5.56 units on a scale Standard Deviation 9.62
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Pain	9.26 units on a scale Standard Deviation 12.11	33.33 units on a scale Standard Deviation 57.74
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Appetite loss	33.33 units on a scale Standard Deviation 33.33	33.33 units on a scale Standard Deviation 57.74
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Constipation	3.70 units on a scale Standard Deviation 11.11	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Financial difficulties	7.41 units on a scale Standard Deviation 14.70	33.33 units on a scale Standard Deviation 57.74
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Pain	18.52 units on a scale Standard Deviation 22.74	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Appetite loss	33.33 units on a scale Standard Deviation 33.33	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Constipation	11.11 units on a scale Standard Deviation 23.57	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Emotional Functioning	81.94 units on a scale Standard Deviation 30.92	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Cognitive Functioning	75.00 units on a scale Standard Deviation 41.83	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Social Functioning	88.89 units on a scale Standard Deviation 20.18	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Fatigue	25.93 units on a scale Standard Deviation 37.62	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Nausea, vomiting	5.56 units on a scale Standard Deviation 13.61	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Pain	13.89 units on a scale Standard Deviation 22.15	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Nausea, vomiting	12.50 units on a scale Standard Deviation 25.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Physical functioning	96.67 units on a scale Standard Deviation 4.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: GHS	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Physical functioning	96.67 units on a scale Standard Deviation 4.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Insomnia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Cognitive Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Fatigue	22.22 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Emotional Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Cognitive Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Insomnia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: GHS	83.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Physical functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Insomnia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Fatigue	5.56 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Fatigue	5.56 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Nausea, vomiting	8.33 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Financial difficulties	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: GHS	83.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Physical functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Fatigue	11.11 units on a scale Standard Deviation 15.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Insomnia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Appetite loss	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Diarrhea	50.00 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Financial difficulties	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Role functioning	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Diarrhea	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Role functioning	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Physical functioning	79.05 units on a scale Standard Deviation 19.89	75.00 units on a scale Standard Deviation 19.15
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Role functioning	80.95 units on a scale Standard Deviation 25.20	70.83 units on a scale Standard Deviation 28.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Emotional Functioning	75.69 units on a scale Standard Deviation 23.15	87.50 units on a scale Standard Deviation 15.96
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Cognitive Functioning	76.39 units on a scale Standard Deviation 20.67	87.50 units on a scale Standard Deviation 25.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Social Functioning	80.56 units on a scale Standard Deviation 26.43	83.33 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Fatigue	34.92 units on a scale Standard Deviation 25.08	27.78 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Nausea, vomiting	5.95 units on a scale Standard Deviation 12.42	16.67 units on a scale Standard Deviation 13.61
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Appetite loss	23.81 units on a scale Standard Deviation 33.15	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Role functioning	80.56 units on a scale Standard Deviation 20.01	63.33 units on a scale Standard Deviation 41.50
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Emotional Functioning	80.09 units on a scale Standard Deviation 20.64	81.67 units on a scale Standard Deviation 22.36
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Fatigue	29.63 units on a scale Standard Deviation 25.57	37.78 units on a scale Standard Deviation 20.18
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C31D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Diarrhea	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C32D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C33D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Fatigue	11.11 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C34D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C35D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C36D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Fatigue	11.11 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C37D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C38D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C39D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C40D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Nausea, vomiting	8.33 units on a scale Standard Deviation 16.42	6.67 units on a scale Standard Deviation 14.91
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C41D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Pain	18.52 units on a scale Standard Deviation 24.85	30.00 units on a scale Standard Deviation 27.39
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Insomnia	23.53 units on a scale Standard Deviation 28.30	20.00 units on a scale Standard Deviation 18.26
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Appetite loss	25.93 units on a scale Standard Deviation 37.15	20.00 units on a scale Standard Deviation 44.72
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C42D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Constipation	3.70 units on a scale Standard Deviation 10.78	26.67 units on a scale Standard Deviation 43.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C43D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Diarrhea	35.19 units on a scale Standard Deviation 21.30	20.00 units on a scale Standard Deviation 29.81
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Financial difficulties	11.11 units on a scale Standard Deviation 19.80	40.0 units on a scale Standard Deviation 43.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: GHS	65.83 units on a scale Standard Deviation 24.99	60.56 units on a scale Standard Deviation 25.87
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Physical functioning	74.70 units on a scale Standard Deviation 22.17	70.22 units on a scale Standard Deviation 27.24
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Pain	30.33 units on a scale Standard Deviation 32.24	30.00 units on a scale Standard Deviation 30.99
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C1D1: Financial difficulties	20.41 units on a scale Standard Deviation 32.50	22.22 units on a scale Standard Deviation 34.88
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Physical functioning	76.82 units on a scale Standard Deviation 22.76	79.49 units on a scale Standard Deviation 13.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Role functioning	73.86 units on a scale Standard Deviation 31.00	82.05 units on a scale Standard Deviation 27.61
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Emotional Functioning	79.73 units on a scale Standard Deviation 21.89	82.69 units on a scale Standard Deviation 13.38
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Cognitive Functioning	81.44 units on a scale Standard Deviation 19.76	76.92 units on a scale Standard Deviation 30.08
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Social Functioning	79.92 units on a scale Standard Deviation 26.06	80.77 units on a scale Standard Deviation 20.24
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Fatigue	38.51 units on a scale Standard Deviation 27.25	41.88 units on a scale Standard Deviation 26.89
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Pain	22.35 units on a scale Standard Deviation 25.66	20.51 units on a scale Standard Deviation 22.72
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Dyspnoea	20.45 units on a scale Standard Deviation 25.13	20.51 units on a scale Standard Deviation 16.88
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Diarrhea	54.55 units on a scale Standard Deviation 26.99	38.46 units on a scale Standard Deviation 29.96
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C2D1: Financial difficulties	18.18 units on a scale Standard Deviation 25.37	23.08 units on a scale Standard Deviation 34.39
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: GHS	65.21 units on a scale Standard Deviation 21.84	54.86 units on a scale Standard Deviation 25.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Role functioning	73.50 units on a scale Standard Deviation 28.02	62.50 units on a scale Standard Deviation 41.51
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Emotional Functioning	79.17 units on a scale Standard Deviation 23.49	71.53 units on a scale Standard Deviation 18.28
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Cognitive Functioning	80.83 units on a scale Standard Deviation 24.33	73.61 units on a scale Standard Deviation 33.68
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Social Functioning	82.92 units on a scale Standard Deviation 21.51	65.28 units on a scale Standard Deviation 24.06
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Fatigue	36.47 units on a scale Standard Deviation 27.92	47.22 units on a scale Standard Deviation 28.48
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Nausea, vomiting	14.10 units on a scale Standard Deviation 20.43	15.28 units on a scale Standard Deviation 15.01
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Pain	22.92 units on a scale Standard Deviation 29.40	44.44 units on a scale Standard Deviation 35.06
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Diarrhea	54.17 units on a scale Standard Deviation 28.93	38.89 units on a scale Standard Deviation 31.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C3D1: Financial difficulties	17.09 units on a scale Standard Deviation 26.35	33.33 units on a scale Standard Deviation 34.82
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: GHS	69.44 units on a scale Standard Deviation 19.20	53.12 units on a scale Standard Deviation 22.69
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Physical functioning	82.47 units on a scale Standard Deviation 15.30	55.00 units on a scale Standard Deviation 30.81
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Role functioning	82.10 units on a scale Standard Deviation 23.08	56.25 units on a scale Standard Deviation 33.26
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Emotional Functioning	87.04 units on a scale Standard Deviation 14.86	67.71 units on a scale Standard Deviation 24.17
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Cognitive Functioning	85.80 units on a scale Standard Deviation 15.12	66.67 units on a scale Standard Deviation 30.86
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Social Functioning	88.27 units on a scale Standard Deviation 18.95	66.67 units on a scale Standard Deviation 26.73
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Fatigue	30.04 units on a scale Standard Deviation 21.53	48.61 units on a scale Standard Deviation 29.66
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Pain	17.28 units on a scale Standard Deviation 18.77	41.67 units on a scale Standard Deviation 29.55
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Dyspnoea	18.52 units on a scale Standard Deviation 23.27	33.33 units on a scale Standard Deviation 35.63
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Insomnia	13.58 units on a scale Standard Deviation 24.91	25.00 units on a scale Standard Deviation 38.83
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Appetite loss	29.63 units on a scale Standard Deviation 29.72	37.50 units on a scale Standard Deviation 33.03
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Constipation	4.94 units on a scale Standard Deviation 12.07	20.83 units on a scale Standard Deviation 35.36
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Diarrhea	53.09 units on a scale Standard Deviation 31.02	33.33 units on a scale Standard Deviation 25.20
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C4D1: Financial difficulties	8.64 units on a scale Standard Deviation 19.81	25.00 units on a scale Standard Deviation 29.55
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: GHS	66.67 units on a scale Standard Deviation 22.88	54.76 units on a scale Standard Deviation 27.58
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Role functioning	77.16 units on a scale Standard Deviation 28.17	40.48 units on a scale Standard Deviation 40.66
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Emotional Functioning	80.25 units on a scale Standard Deviation 21.33	77.38 units on a scale Standard Deviation 17.82
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Cognitive Functioning	83.95 units on a scale Standard Deviation 17.59	69.05 units on a scale Standard Deviation 39.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Fatigue	32.51 units on a scale Standard Deviation 24.83	53.70 units on a scale Standard Deviation 34.72
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Nausea, vomiting	7.41 units on a scale Standard Deviation 14.12	9.52 units on a scale Standard Deviation 13.11
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Pain	13.58 units on a scale Standard Deviation 21.70	50.00 units on a scale Standard Deviation 38.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Dyspnoea	25.93 units on a scale Standard Deviation 23.27	28.57 units on a scale Standard Deviation 29.99
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Insomnia	19.75 units on a scale Standard Deviation 26.57	33.33 units on a scale Standard Deviation 43.03
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Appetite loss	35.80 units on a scale Standard Deviation 31.93	33.33 units on a scale Standard Deviation 38.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C5D1: Constipation	7.41 units on a scale Standard Deviation 16.88	19.05 units on a scale Standard Deviation 26.23
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: GHS	68.06 units on a scale Standard Deviation 23.44	71.67 units on a scale Standard Deviation 11.18
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C6D1: Physical functioning	79.63 units on a scale Standard Deviation 18.50	69.33 units on a scale Standard Deviation 36.39
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Constipation	5.56 units on a scale Standard Deviation 12.97	33.33 units on a scale Standard Deviation 27.22
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Diarrhea	41.67 units on a scale Standard Deviation 32.18	16.67 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C7D1: Financial difficulties	15.15 units on a scale Standard Deviation 22.92	33.33 units on a scale Standard Deviation 47.14
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: GHS	75.00 units on a scale Standard Deviation 19.25	61.11 units on a scale Standard Deviation 25.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Physical functioning	82.22 units on a scale Standard Deviation 13.43	57.78 units on a scale Standard Deviation 47.30
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Cognitive Functioning	75.64 units on a scale Standard Deviation 25.11	94.44 units on a scale Standard Deviation 9.62
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Fatigue	29.63 units on a scale Standard Deviation 24.77	55.56 units on a scale Standard Deviation 44.44
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	16.67 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Pain	10.26 units on a scale Standard Deviation 14.50	33.33 units on a scale Standard Deviation 44.10
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Dyspnoea	22.22 units on a scale Standard Deviation 21.71	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Insomnia	25.00 units on a scale Standard Deviation 35.18	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Appetite loss	22.22 units on a scale Standard Deviation 32.82	33.33 units on a scale Standard Deviation 57.74
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Constipation	8.33 units on a scale Standard Deviation 20.72	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Diarrhea	33.33 units on a scale Standard Deviation 27.22	66.67 units on a scale Standard Deviation 33.33
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C8D1: Financial difficulties	10.26 units on a scale Standard Deviation 16.01	33.33 units on a scale Standard Deviation 57.74
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: GHS	77.78 units on a scale Standard Deviation 16.14	75.00 units on a scale Standard Deviation 14.43
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Physical functioning	81.48 units on a scale Standard Deviation 14.44	55.56 units on a scale Standard Deviation 50.92
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Role functioning	88.89 units on a scale Standard Deviation 16.67	55.56 units on a scale Standard Deviation 50.92
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Emotional Functioning	81.48 units on a scale Standard Deviation 22.74	61.11 units on a scale Standard Deviation 25.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Cognitive Functioning	77.78 units on a scale Standard Deviation 27.64	100.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Social Functioning	92.59 units on a scale Standard Deviation 12.11	72.22 units on a scale Standard Deviation 25.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Fatigue	33.33 units on a scale Standard Deviation 28.33	55.56 units on a scale Standard Deviation 50.92
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Dyspnoea	22.22 units on a scale Standard Deviation 23.57	22.22 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Insomnia	25.93 units on a scale Standard Deviation 27.78	44.44 units on a scale Standard Deviation 50.92
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C9D1: Diarrhea	25.93 units on a scale Standard Deviation 22.22	33.33 units on a scale Standard Deviation 33.33
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: GHS	74.07 units on a scale Standard Deviation 26.17	50.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Physical functioning	82.96 units on a scale Standard Deviation 14.57	60.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Role functioning	79.63 units on a scale Standard Deviation 23.24	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Emotional Functioning	83.33 units on a scale Standard Deviation 20.83	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Cognitive Functioning	72.22 units on a scale Standard Deviation 32.27	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Social Functioning	85.19 units on a scale Standard Deviation 19.44	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Fatigue	35.80 units on a scale Standard Deviation 30.32	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Nausea, vomiting	9.26 units on a scale Standard Deviation 27.78	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Dyspnoea	25.93 units on a scale Standard Deviation 32.39	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Insomnia	33.33 units on a scale Standard Deviation 33.33	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Diarrhea	37.04 units on a scale Standard Deviation 20.03	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C10D1: Financial difficulties	11.11 units on a scale Standard Deviation 16.67	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: GHS	72.22 units on a scale Standard Deviation 24.65	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Physical functioning	82.96 units on a scale Standard Deviation 14.95	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Role functioning	79.63 units on a scale Standard Deviation 20.03	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Emotional Functioning	83.33 units on a scale Standard Deviation 22.44	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Cognitive Functioning	77.78 units on a scale Standard Deviation 25.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Social Functioning	90.74 units on a scale Standard Deviation 14.70	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Fatigue	24.69 units on a scale Standard Deviation 22.07	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Nausea, vomiting	5.56 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Pain	12.96 units on a scale Standard Deviation 18.22	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Dyspnoea	22.22 units on a scale Standard Deviation 33.33	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Insomnia	25.00 units on a scale Standard Deviation 34.50	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Appetite loss	25.93 units on a scale Standard Deviation 32.39	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Constipation	7.41 units on a scale Standard Deviation 14.70	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Diarrhea	33.33 units on a scale Standard Deviation 16.67	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C11D1: Financial difficulties	7.41 units on a scale Standard Deviation 14.70	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: GHS	77.78 units on a scale Standard Deviation 27.22	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Physical functioning	85.56 units on a scale Standard Deviation 19.96	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Role functioning	91.67 units on a scale Standard Deviation 20.41	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Dyspnoea	27.78 units on a scale Standard Deviation 44.31	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Insomnia	33.33 units on a scale Standard Deviation 42.16	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Appetite loss	22.22 units on a scale Standard Deviation 40.37	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Diarrhea	22.22 units on a scale Standard Deviation 17.21	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C12D1: Financial difficulties	5.56 units on a scale Standard Deviation 13.61	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: GHS	66.67 units on a scale Standard Deviation 33.33	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Physical functioning	86.67 units on a scale Standard Deviation 12.17	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Role functioning	83.33 units on a scale Standard Deviation 33.33	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Emotional Functioning	61.11 units on a scale Standard Deviation 33.68	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Cognitive Functioning	55.56 units on a scale Standard Deviation 38.49	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Social Functioning	77.78 units on a scale Standard Deviation 38.49	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Fatigue	40.28 units on a scale Standard Deviation 30.56	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Pain	25.00 units on a scale Standard Deviation 28.87	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Dyspnoea	33.33 units on a scale Standard Deviation 38.49	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Insomnia	50.00 units on a scale Standard Deviation 43.03	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Appetite loss	41.67 units on a scale Standard Deviation 50.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Constipation	16.67 units on a scale Standard Deviation 19.25	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Diarrhea	11.11 units on a scale Standard Deviation 19.25	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C13D1: Financial difficulties	11.11 units on a scale Standard Deviation 19.25	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: GHS	79.17 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Emotional Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Cognitive Functioning	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Fatigue	16.67 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Nausea, vomiting	8.33 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Dyspnoea	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Insomnia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Constipation	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C14D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Emotional Functioning	95.83 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Cognitive Functioning	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Fatigue	5.56 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Constipation	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C15D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: GHS	87.50 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Physical functioning	96.67 units on a scale Standard Deviation 4.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Emotional Functioning	87.50 units on a scale Standard Deviation 17.68	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Cognitive Functioning	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Fatigue	11.11 units on a scale Standard Deviation 15.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Pain	8.33 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Insomnia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C16D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: GHS	87.50 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Physical functioning	96.67 units on a scale Standard Deviation 4.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Emotional Functioning	87.50 units on a scale Standard Deviation 17.68	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Cognitive Functioning	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Fatigue	11.11 units on a scale Standard Deviation 15.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Nausea, vomiting	8.33 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Insomnia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Appetite loss	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C17D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: GHS	79.17 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Physical functioning	96.67 units on a scale Standard Deviation 4.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Emotional Functioning	87.50 units on a scale Standard Deviation 17.68	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Cognitive Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Fatigue	5.56 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Nausea, vomiting	8.33 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Insomnia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Appetite loss	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C18D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: GHS	87.50 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Physical functioning	96.67 units on a scale Standard Deviation 4.71	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Emotional Functioning	95.83 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Pain	16.67 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Insomnia	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Diarrhea	50.00 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C19D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: GHS	83.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Physical functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Fatigue	5.56 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C20D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: GHS	83.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Physical functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Emotional Functioning	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Cognitive Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Fatigue	5.56 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C21D1: Insomnia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Emotional Functioning	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Cognitive Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Fatigue	5.56 units on a scale Standard Deviation 7.86	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Nausea, vomiting	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Diarrhea	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C22D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: GHS	83.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Physical functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Emotional Functioning	87.50 units on a scale Standard Deviation 17.68	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Cognitive Functioning	83.33 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Insomnia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Diarrhea	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C23D1: Financial difficulties	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: GHS	83.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Physical functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Emotional Functioning	83.33 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Cognitive Functioning	83.33 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Insomnia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Appetite loss	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Constipation	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C24D1: Diarrhea	50.00 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Role functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Emotional Functioning	95.83 units on a scale Standard Deviation 5.89	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Cognitive Functioning	91.67 units on a scale Standard Deviation 11.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C25D1: Social Functioning	100.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C26D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C27D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Diarrhea	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C29D1: Financial difficulties	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: GHS	83.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Physical functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Role functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Emotional Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Cognitive Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Social Functioning	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Fatigue	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Nausea, vomiting	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Insomnia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Appetite loss	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Constipation	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score C30D1: Diarrhea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—

SECONDARY outcome

Timeframe: Baseline (C1D1), C2D1 thereafter every subsequent cycle up to C43

QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=15 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Dyspnoea	25.85 units on a scale Standard Deviation 22.84	26.98 units on a scale Standard Deviation 21.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Coughing	33.33 units on a scale Standard Deviation 30.12	33.33 units on a scale Standard Deviation 25.20
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Peripheral neuropathy	10.00 units on a scale Standard Deviation 18.13	13.33 units on a scale Standard Deviation 24.56
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Alopecia	8.16 units on a scale Standard Deviation 25.94	22.22 units on a scale Standard Deviation 37.09
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Sore mouth	36.36 units on a scale Standard Deviation 32.00	27.78 units on a scale Standard Deviation 23.92
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Dyspnoea	15.81 units on a scale Standard Deviation 16.08	31.94 units on a scale Standard Deviation 26.85
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Sore mouth	7.41 units on a scale Standard Deviation 14.70	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Other pain	22.22 units on a scale Standard Deviation 23.57	55.56 units on a scale Standard Deviation 50.92
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Dysphagia	11.11 units on a scale Standard Deviation 16.67	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Peripheral neuropathy	16.67 units on a scale Standard Deviation 33.33	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Alopecia	16.67 units on a scale Standard Deviation 19.25	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Chest pain	33.33 units on a scale Standard Deviation 38.49	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Dysphagia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Peripheral neuropathy	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Hemoptysis	2.00 units on a scale Standard Deviation 10.45	4.44 units on a scale Standard Deviation 11.73
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Sore mouth	3.33 units on a scale Standard Deviation 10.10	6.67 units on a scale Standard Deviation 18.69
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Dysphagia	2.67 units on a scale Standard Deviation 9.13	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Chest pain	14.67 units on a scale Standard Deviation 27.07	20.00 units on a scale Standard Deviation 30.34
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Arm pain	20.00 units on a scale Standard Deviation 30.12	17.78 units on a scale Standard Deviation 33.01
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C1D1: Other pain	32.00 units on a scale Standard Deviation 32.96	37.78 units on a scale Standard Deviation 33.01
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Dyspnoea	18.69 units on a scale Standard Deviation 20.02	26.85 units on a scale Standard Deviation 23.43
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Coughing	19.70 units on a scale Standard Deviation 19.45	33.33 units on a scale Standard Deviation 24.62
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Hemoptysis	2.27 units on a scale Standard Deviation 8.50	5.56 units on a scale Standard Deviation 12.97
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Dysphagia	7.58 units on a scale Standard Deviation 14.13	11.11 units on a scale Standard Deviation 16.41
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Peripheral neuropathy	12.12 units on a scale Standard Deviation 20.45	13.89 units on a scale Standard Deviation 22.29
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Alopecia	6.06 units on a scale Standard Deviation 20.68	8.33 units on a scale Standard Deviation 15.08
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Chest pain	10.61 units on a scale Standard Deviation 21.29	13.89 units on a scale Standard Deviation 17.16
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Arm pain	14.39 units on a scale Standard Deviation 20.83	19.44 units on a scale Standard Deviation 38.82
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C2D1: Other pain	22.76 units on a scale Standard Deviation 26.29	16.67 units on a scale Standard Deviation 30.15
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Dyspnoea	21.37 units on a scale Standard Deviation 23.69	18.52 units on a scale Standard Deviation 14.47
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Coughing	23.08 units on a scale Standard Deviation 20.45	41.67 units on a scale Standard Deviation 25.13
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Hemoptysis	1.67 units on a scale Standard Deviation 7.36	5.56 units on a scale Standard Deviation 12.97
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Sore mouth	30.00 units on a scale Standard Deviation 31.85	16.67 units on a scale Standard Deviation 22.47
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Dysphagia	11.67 units on a scale Standard Deviation 24.52	11.11 units on a scale Standard Deviation 21.71
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Peripheral neuropathy	16.24 units on a scale Standard Deviation 24.03	22.22 units on a scale Standard Deviation 25.95
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Alopecia	4.17 units on a scale Standard Deviation 13.48	8.33 units on a scale Standard Deviation 15.08
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Chest pain	11.67 units on a scale Standard Deviation 23.33	19.44 units on a scale Standard Deviation 22.29
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Arm pain	8.33 units on a scale Standard Deviation 16.45	25.00 units on a scale Standard Deviation 32.18
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C3D1: Other pain	23.08 units on a scale Standard Deviation 26.66	33.33 units on a scale Standard Deviation 30.43
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Coughing	21.79 units on a scale Standard Deviation 20.96	41.67 units on a scale Standard Deviation 23.57
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Hemoptysis	2.56 units on a scale Standard Deviation 9.06	4.17 units on a scale Standard Deviation 11.79
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Sore mouth	19.23 units on a scale Standard Deviation 19.26	20.83 units on a scale Standard Deviation 24.80
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Dysphagia	7.69 units on a scale Standard Deviation 14.32	16.67 units on a scale Standard Deviation 30.86
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Peripheral neuropathy	19.23 units on a scale Standard Deviation 28.55	25.00 units on a scale Standard Deviation 15.43
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Alopecia	6.41 units on a scale Standard Deviation 21.12	4.17 units on a scale Standard Deviation 11.79
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Chest pain	3.85 units on a scale Standard Deviation 10.86	20.83 units on a scale Standard Deviation 30.54
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Arm pain	7.69 units on a scale Standard Deviation 17.15	29.17 units on a scale Standard Deviation 33.03
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C4D1: Other pain	28.00 units on a scale Standard Deviation 24.87	37.50 units on a scale Standard Deviation 27.82
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Dyspnoea	20.51 units on a scale Standard Deviation 17.12	20.63 units on a scale Standard Deviation 13.50
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Coughing	25.64 units on a scale Standard Deviation 17.15	42.86 units on a scale Standard Deviation 16.27
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Hemoptysis	1.28 units on a scale Standard Deviation 6.54	4.76 units on a scale Standard Deviation 12.60
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Sore mouth	19.23 units on a scale Standard Deviation 25.25	23.81 units on a scale Standard Deviation 25.20
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Dysphagia	7.69 units on a scale Standard Deviation 17.15	14.29 units on a scale Standard Deviation 26.23
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Peripheral neuropathy	16.67 units on a scale Standard Deviation 27.08	19.05 units on a scale Standard Deviation 17.82
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Alopecia	8.97 units on a scale Standard Deviation 22.23	9.52 units on a scale Standard Deviation 16.27
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Chest pain	8.97 units on a scale Standard Deviation 17.78	9.52 units on a scale Standard Deviation 16.27
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Arm pain	10.26 units on a scale Standard Deviation 22.65	23.81 units on a scale Standard Deviation 37.09
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C5D1: Other pain	21.33 units on a scale Standard Deviation 30.25	33.33 units on a scale Standard Deviation 38.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Dyspnoea	17.90 units on a scale Standard Deviation 23.84	20.00 units on a scale Standard Deviation 14.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Coughing	27.78 units on a scale Standard Deviation 20.61	20.00 units on a scale Standard Deviation 18.26
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Hemoptysis	3.70 units on a scale Standard Deviation 10.78	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Sore mouth	22.22 units on a scale Standard Deviation 22.87	26.67 units on a scale Standard Deviation 27.89
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Dysphagia	3.70 units on a scale Standard Deviation 10.78	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Peripheral neuropathy	16.67 units on a scale Standard Deviation 23.57	46.67 units on a scale Standard Deviation 38.01
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Alopecia	11.11 units on a scale Standard Deviation 16.17	20.00 units on a scale Standard Deviation 18.26
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Chest pain	7.41 units on a scale Standard Deviation 18.28	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Arm pain	9.26 units on a scale Standard Deviation 15.36	6.67 units on a scale Standard Deviation 14.91
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C6D1: Other pain	16.67 units on a scale Standard Deviation 24.34	40.00 units on a scale Standard Deviation 43.46
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Dyspnoea	17.46 units on a scale Standard Deviation 18.85	19.44 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Coughing	21.43 units on a scale Standard Deviation 21.11	16.67 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Hemoptysis	2.38 units on a scale Standard Deviation 8.91	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Sore mouth	26.19 units on a scale Standard Deviation 26.73	16.67 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Dysphagia	11.90 units on a scale Standard Deviation 21.11	8.33 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Peripheral neuropathy	19.05 units on a scale Standard Deviation 31.25	16.67 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Alopecia	11.90 units on a scale Standard Deviation 16.57	8.33 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Chest pain	4.76 units on a scale Standard Deviation 12.10	8.33 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Arm pain	11.90 units on a scale Standard Deviation 21.11	8.33 units on a scale Standard Deviation 16.67
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C7D1: Other pain	15.38 units on a scale Standard Deviation 22.01	25.00 units on a scale Standard Deviation 31.91
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Dyspnoea	15.38 units on a scale Standard Deviation 14.01	29.63 units on a scale Standard Deviation 27.96
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Coughing	28.21 units on a scale Standard Deviation 26.69	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Hemoptysis	5.13 units on a scale Standard Deviation 12.52	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Sore mouth	12.82 units on a scale Standard Deviation 16.88	22.22 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Dysphagia	7.69 units on a scale Standard Deviation 14.62	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Peripheral neuropathy	15.38 units on a scale Standard Deviation 22.01	33.33 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Alopecia	12.82 units on a scale Standard Deviation 16.88	22.22 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Chest pain	7.69 units on a scale Standard Deviation 14.62	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Arm pain	8.33 units on a scale Standard Deviation 15.08	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C8D1: Other pain	23.08 units on a scale Standard Deviation 21.01	22.22 units on a scale Standard Deviation 38.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Dyspnoea	23.46 units on a scale Standard Deviation 20.37	25.93 units on a scale Standard Deviation 23.13
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Coughing	29.63 units on a scale Standard Deviation 20.03	11.11 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Hemoptysis	3.70 units on a scale Standard Deviation 11.11	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Dysphagia	11.11 units on a scale Standard Deviation 16.67	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Peripheral neuropathy	11.11 units on a scale Standard Deviation 16.67	44.44 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Alopecia	8.33 units on a scale Standard Deviation 15.43	22.22 units on a scale Standard Deviation 19.25
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Chest pain	7.41 units on a scale Standard Deviation 14.70	0.00 units on a scale Standard Deviation 0.00
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C9D1: Arm pain	14.81 units on a scale Standard Deviation 24.22	22.22 units on a scale Standard Deviation 38.49
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Dyspnoea	23.46 units on a scale Standard Deviation 25.73	44.44 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Coughing	25.93 units on a scale Standard Deviation 22.22	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Hemoptysis	3.70 units on a scale Standard Deviation 11.11	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Sore mouth	11.11 units on a scale Standard Deviation 23.57	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Peripheral neuropathy	18.52 units on a scale Standard Deviation 24.22	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Alopecia	14.81 units on a scale Standard Deviation 17.57	66.67 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Chest pain	3.70 units on a scale Standard Deviation 11.11	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Arm pain	14.81 units on a scale Standard Deviation 24.22	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C10D1: Other pain	22.22 units on a scale Standard Deviation 28.87	100.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Dyspnoea	23.46 units on a scale Standard Deviation 28.02	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Coughing	25.93 units on a scale Standard Deviation 22.22	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Hemoptysis	3.70 units on a scale Standard Deviation 11.11	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Sore mouth	11.11 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Dysphagia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Peripheral neuropathy	14.81 units on a scale Standard Deviation 33.79	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Alopecia	11.11 units on a scale Standard Deviation 16.67	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Chest pain	11.11 units on a scale Standard Deviation 16.67	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Arm pain	14.81 units on a scale Standard Deviation 24.22	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C11D1: Other pain	12.50 units on a scale Standard Deviation 24.80	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Dyspnoea	22.22 units on a scale Standard Deviation 34.43	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Coughing	27.78 units on a scale Standard Deviation 25.09	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Hemoptysis	5.56 units on a scale Standard Deviation 13.61	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Sore mouth	5.56 units on a scale Standard Deviation 13.61	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Dysphagia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Peripheral neuropathy	5.56 units on a scale Standard Deviation 13.61	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Alopecia	16.67 units on a scale Standard Deviation 18.26	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Chest pain	22.22 units on a scale Standard Deviation 34.43	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Arm pain	22.22 units on a scale Standard Deviation 34.43	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C12D1: Other pain	22.22 units on a scale Standard Deviation 40.37	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Dyspnoea	27.78 units on a scale Standard Deviation 32.08	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Coughing	41.67 units on a scale Standard Deviation 16.67	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Hemoptysis	8.33 units on a scale Standard Deviation 16.67	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Sore mouth	16.67 units on a scale Standard Deviation 19.25	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Dysphagia	8.33 units on a scale Standard Deviation 16.67	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Arm pain	33.33 units on a scale Standard Deviation 38.49	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C13D1: Other pain	33.33 units on a scale Standard Deviation 38.46	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Dysphagia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C14D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Dysphagia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C15D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Coughing	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Dysphagia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C16D1: Other pain	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Dysphagia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C17D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Coughing	50.00 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Dysphagia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C18D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Coughing	33.33 units on a scale Standard Deviation 33.33	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Dysphagia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C19D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Dysphagia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C20D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Dysphagia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C21D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Dysphagia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C22D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Dyspnoea	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Dysphagia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Alopecia	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C23D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C24D1: Other pain	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Coughing	33.33 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Dysphagia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Alopecia	16.67 units on a scale Standard Deviation 23.57	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Arm pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C25D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C26D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C27D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Chest pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C29D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Coughing	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Hemoptysis	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C30D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C31D1: Other pain	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C32D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C33D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C34D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C35D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C36D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C37D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C38D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Coughing	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C39D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C40D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C41D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Coughing	33.33 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Sore mouth	0.00 units on a scale Standard Deviation 0.00	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Hemoptysis	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Sore mouth	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Dysphagia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Peripheral neuropathy	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Other pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Alopecia	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Chest pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C42D1: Arm pain	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Dyspnoea	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score C43D1: Coughing	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—

SECONDARY outcome

Timeframe: Baseline (C1D1), C2D1 thereafter every subsequent cycle up to C43

Self-administered questionnaire to measure health-related quality of life (QoL) of adult participants suffering from skin disease; 10 questions concerning participants' perception of impact of their disease over last week encompassing aspects such as symptoms or feelings, daily activities, leisure, work or school, personal relationships and treatment. Questions scored on a 4-point Likert scale: 0 (not relevant), 1 (a little), 2 (a lot), and 3 (very much). Scores of individual questions (0-3) were added to yield a total score (0-30); higher score = greater impairment of participant's QoL.

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=15 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Dermatology Life Quality Index (DLQI) Score C5D1	4.67 units on a scale Standard Deviation 4.12	6.00 units on a scale Standard Deviation 7.62
Dermatology Life Quality Index (DLQI) Score C1D1	0.38 units on a scale Standard Deviation 0.54	0.80 units on a scale Standard Deviation 1.52
Dermatology Life Quality Index (DLQI) Score C33D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C39D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C6D1	4.39 units on a scale Standard Deviation 4.65	6.00 units on a scale Standard Deviation 6.40
Dermatology Life Quality Index (DLQI) Score C4D1	3.56 units on a scale Standard Deviation 3.62	5.13 units on a scale Standard Deviation 5.06
Dermatology Life Quality Index (DLQI) Score C2D1	3.34 units on a scale Standard Deviation 4.37	2.08 units on a scale Standard Deviation 2.22
Dermatology Life Quality Index (DLQI) Score C3D1	4.08 units on a scale Standard Deviation 4.31	3.08 units on a scale Standard Deviation 3.99
Dermatology Life Quality Index (DLQI) Score C7D1	4.00 units on a scale Standard Deviation 5.28	5.00 units on a scale Standard Deviation 6.06
Dermatology Life Quality Index (DLQI) Score C8D1	3.31 units on a scale Standard Deviation 3.57	3.67 units on a scale Standard Deviation 3.21
Dermatology Life Quality Index (DLQI) Score C9D1	1.78 units on a scale Standard Deviation 2.49	2.50 units on a scale Standard Deviation 3.54
Dermatology Life Quality Index (DLQI) Score C10D1	2.22 units on a scale Standard Deviation 2.54	8.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.
Dermatology Life Quality Index (DLQI) Score C11D1	2.78 units on a scale Standard Deviation 3.35	—
Dermatology Life Quality Index (DLQI) Score C12D1	2.00 units on a scale Standard Deviation 3.95	—
Dermatology Life Quality Index (DLQI) Score C13D1	4.00 units on a scale Standard Deviation 3.65	—
Dermatology Life Quality Index (DLQI) Score C14D1	1.50 units on a scale Standard Deviation 0.71	—
Dermatology Life Quality Index (DLQI) Score C15D1	1.00 units on a scale Standard Deviation 1.41	—
Dermatology Life Quality Index (DLQI) Score C16D1	2.00 units on a scale Standard Deviation 0.00	—
Dermatology Life Quality Index (DLQI) Score C17D1	0.50 units on a scale Standard Deviation 0.71	—
Dermatology Life Quality Index (DLQI) Score C18D1	0.50 units on a scale Standard Deviation 0.71	—
Dermatology Life Quality Index (DLQI) Score C19D1	1.00 units on a scale Standard Deviation 1.41	—
Dermatology Life Quality Index (DLQI) Score C20D1	0.50 units on a scale Standard Deviation 0.71	—
Dermatology Life Quality Index (DLQI) Score C21D1	1.00 units on a scale Standard Deviation 1.41	—
Dermatology Life Quality Index (DLQI) Score C22D1	1.00 units on a scale Standard Deviation 1.41	—
Dermatology Life Quality Index (DLQI) Score C23D1	8.00 units on a scale Standard Deviation 11.31	—
Dermatology Life Quality Index (DLQI) Score C24D1	1.00 units on a scale Standard Deviation 1.41	—
Dermatology Life Quality Index (DLQI) Score C25D1	3.00 units on a scale Standard Deviation 0.00	—
Dermatology Life Quality Index (DLQI) Score C26D1	2.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C27D1	1.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C29D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C30D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C31D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C32D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C34D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C35D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C36D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C37D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C38D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C40D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C41D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C42D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—
Dermatology Life Quality Index (DLQI) Score C43D1	0.00 units on a scale Standard Deviation NA Standard deviation was not estimable since only one participant was evaluable.	—

SECONDARY outcome

Timeframe: Month 6

Population: As-enrolled population included all participants who were enrolled in the study.

PFS is defined as time in weeks from randomization to the first documentation of objective tumor progression or death due to any cause. PFS was calculated as = (first event date minus randomization date plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Outcome measures

Outcome measures
Measure	PF-00299804 (Adenocarcinoma Histology) n=50 Participants Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=16 Participants Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Percentage of Participants With Progression-free Survival (PFS)	24.3 percentage of participants Interval 12.4 to 38.4	8.0 percentage of participants Interval 0.5 to 29.8

Adverse Events

PF-00299804 (Adenocarcinoma Histology)

Serious events: 9 serious events

Other events: 50 other events

Deaths: 0 deaths

PF-00299804 (Non-adenocarcinoma Histology)

Serious events: 6 serious events

Other events: 15 other events

Deaths: 0 deaths

Serious adverse events

Other adverse events

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer, Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER

Measure	PF-00299804 (Adenocarcinoma Histology) n=50 participants at risk Participants with adenocarcinoma histology received PF-00299804 tablet 45 milligram (mg) orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.	PF-00299804 (Non-adenocarcinoma Histology) n=16 participants at risk Participants with non-adenocarcinoma histology received PF-00299804 tablet 45 mg orally once daily in cycles of 21 days until unacceptable toxicity, tumor progression, death, withdrawal from the study or investigator's discretion.
Blood and lymphatic system disorders Anaemia	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Abdominal pain	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	12.5% 2/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Constipation	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	12.5% 2/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Diarrhoea	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Nausea	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Pancreatitis	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Gastrointestinal disorders Vomiting	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
General disorders Asthenia	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
General disorders Disease progression	6.0% 3/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Cystitis	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Infections and infestations Pneumonia	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Metabolism and nutrition disorders Dehydration	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Renal and urinary disorders Renal failure acute	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Dyspnoea	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	2.0% 1/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	4.0% 2/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Respiratory, thoracic and mediastinal disorders Respiratory failure	6.0% 3/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	0.00% 0/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
Vascular disorders Hypotension	0.00% 0/50 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.	6.2% 1/16 The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.